Overcoming the hurdles to achieving glycemic control

Metabolism: Clinical and Experimental

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Shaw, Kenneth M ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; STEROID; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIET; DISEASE COURSE; DRUG RELEASE; ENDOCRINE DISEASE; EXERCISE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LACTIC ACIDOSIS; LIFESTYLE; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; BLOOD; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PATIENT COMPLIANCE;

EID: 33646947300     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.02.001     Document Type: Article

References (13)

1. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in diabetics with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-858
2. Turner R.C., Cull C.A., Frighi V., and Holman RR. Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2212
3. Winocour P.H. Effective diabetes care-a need for realistic targets. BMJ 324 (2002) 1577-1580
4. UK Prospective Diabetes Study Group. UKPDS 16: Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
5. Harrower A. Gliclazide modified release: from once daily administration to 24-hour blood glucose control. Metabolism 49 (2000) 7-11
6. Satoh J., Takahashi K., Takizawa Y., Ishihara H., Hirai M., Katagiri H., et al. Secondary sulfonylurea failure-comparison of period with insulin treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 70 (2005) 291-297
7. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Katsuta H., et al. Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 303 (2003) 112-119
8. Lawton J., Ahmad N., Hallowell N., Hanna L., and Douglas M. Perceptions and experiences of taking oral hypoglycaemic agents amongst people of Pakistani and Indian origin. BMJ 330 (2005) 1247-1250
9. Greenhalgh T. Barriers to concordance with antidiabetic drugs, cultural differences or human nature?. BMJ 330 (2005) 1250
10. Guillausseau P.J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. Diabetes Metab 29 (2003) 79-81
11. Guillausseau P.J. Compliance and optimization of oral antidiabetic therapy. Presse Med 33 (2004) 156-160
12. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 7 (2005) 722-728
13. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34 (2004) 535-542